Home ›
Drugs ›
Adalimumab ›
FDA recalls
Adalimumab
FDA recalls
6 rows
Summary of public sources, not medical advice. This page is an automated summary of public information from the FDA, the National Library of Medicine (DailyMed) and CMS Medicare data. It has not been reviewed by a doctor or pharmacist, may be incomplete, out of date or wrong, and does not list every use, dose, warning, interaction or side effect. Do not start, stop or change any medicine, or take a pill you cannot identify, based on this page: ask your doctor or pharmacist and read the official label. In an emergency call 911; for possible poisoning call Poison Control at 1-800-222-1222. Use of this page is subject to our Medical and Data Disclaimer and Terms of Use .
Date Company and reason Class
Jan 19, 2026 Acme United Corporation Class II · Ongoing Jul 6, 2025 Medline Industries, LP - Northfield Class II · Ongoing Feb 16, 2025 Medline Industries, LP - Northfield Class II · Ongoing Mar 15, 2023 Focus Health Group Inc Class III · Ongoing Jun 28, 2022 McKesson Medical-Surgical Inc. Corporate Office Class II · Terminated Mar 27, 2019 Aurobindo Pharma USA Inc. Class I · Terminated
← Back to Adalimumab
Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).